Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 15/20 | 0.66 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421551 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL15692432 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL12954569 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL13678075 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL16488293 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL18058596 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL12587499 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL303449 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL15196200 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL366908 | 0.91 | SLC5A1 (0.81) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0684254-B1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | claimed |
| US-5830873-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-03 | — | — | US | claimed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-0684254-B1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | disclosed |
| US-5830873-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0684254-A1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | SLC5A1 693/4885SLC5A2 492/4885HPGD 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.